November 14, 2016 09:16 AM ESTUpdated 10:59 AM

Novartis’ ‘breakthrough’ AML drug gets accelerated FDA review; Ocular surges on positive PhIII eye study

Shehla Shakoor

Managing Director

Novartis will get a quick decision from the FDA on its application for PKC412 (midostaurin), its FLT3 drug for acute myeloid leukemia. The agency is …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novartis’ ‘breakthrough’ AML drug gets accelerated FDA review; Ocular surges on positive PhIII eye study

Shehla Shakoor

Managing Director

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CMS explains what went into its first round of drug price negotiations

CagriSema’s weight loss data disappointed. What does Novo do next?

Exclusive: Florida cancer biotech raises $100M Series A

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

PDUFAs for Tonix and Nuvation; Sanofi vaccine partnership; RAPT allergy deal

No­var­tis’ ‘break­through’ AML drug gets ac­cel­er­at­ed FDA re­view; Oc­u­lar surges on pos­i­tive PhI­II eye study

Shehla Shakoor

Managing Director

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

PDU­FAs for Tonix and Nu­va­tion; Sanofi vac­cine part­ner­ship; RAPT al­ler­gy deal

Novartis’ ‘breakthrough’ AML drug gets accelerated FDA review; Ocular surges on positive PhIII eye study

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CMS explains what went into its first round of drug price negotiations

CagriSema’s weight loss data disappointed. What does Novo do next?

Exclusive: Florida cancer biotech raises $100M Series A

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

PDUFAs for Tonix and Nuvation; Sanofi vaccine partnership; RAPT allergy deal